Loading
journalsJournal
Nature Cancer
Nature Cancer is Nature's cancer-specific research journal, launched in 2020, spanning basic biology to translational and clinical cancer studies.
Also called: Nat Cancersrc-nature-cancer
Overview
Nature Cancer (Nat Cancer) is Nature's cancer-specific research journal, launched in 2020, appearing monthly and published by Springer Nature on a hybrid access model. It spans basic biology to translational and clinical cancer studies, publishing tumour biology, immuno-oncology, computational and AI methods for cancer, and early-phase trial correlative science, with a deliberate remit to cover health-policy and access issues as well. Its readers are cancer researchers across the basic-to-clinical spectrum. Within OnCo it has its own Nature Cancer source feed and is linked from the biographies of Todd Golub and Jakob Nikolas Kather, and it is where a reader would look for computational and AI cancer methods and correlative trial science.
Publisher
Springer Nature
Scope
basic cancer biology
Website
Access model
hybrid
Founded
2020
ISSN
2662-1347
Impact factor (2023)
23.5 · Clarivate Journal Citation Reports 2024 (2023 JIF)
rct202335 citations
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
A second publication from the GEMSTONE-302 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
basic2021177 citations
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observational2021501 citations
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
One of the most cited papers Europe PMC returns for Antoine Italiano at Institut Bergonié, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
translational2020185 citations
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma
It joins the pathology (adenosquamous), the transcriptome (basal-like) and the genome (KDM6A, MYC) into one account of the chemotherapy-resistant subtype, and shows a single biopsy can miss it.
Antoine Italiano
Head of Early-Phase Trials and Sarcoma Unit, Institut Bergonié, Bordeaux
SarcomaEarly-phase trialsPrecision oncology
Bordeaux oncologist who led CABONE, the trial that showed cabozantinib shrinks or stabilises osteosarcoma and Ewing sarcoma after standard treatment has failed.
Christian Singer
Vice-President
Breast cancerGynaecological oncologyHereditary cancer
Gynaecological oncologist at the Medical University of Vienna and ABCSG Vice-President, known for work on breast cancer and hereditary cancer risk.
Jakob Nikolas Kather
Professor of Clinical Artificial Intelligence, Else Kröner Fresenius Center for Digital Health, TU Dresden; Medical Oncologist, NCT Dresden
AI in oncologyDeep learning on histologyBiomarker prediction from slides
Showed that deep learning can read genetic features like microsatellite instability directly from routine pathology slides.
Sascha Dietrich
Deputy Medical Director
HaematologyLymphomaFunctional precision oncology
Haematologist-oncologist and Deputy Medical Director at University Hospital Düsseldorf, known for drug-response profiling in lymphoma and leukaemia.
Todd R. Golub
Director, Broad Institute; Charles A. Dana Investigator, Dana-Farber
Cancer genomicsFunctional genomicsPRISM drug screening
Showed that gene expression could classify cancers, then built the Broad into the engine of cancer genomics.
Notes
top- Holds: Cancer biology and translational studies across the spectrum. Access: Paywalled.
rctNature Cancer 202335 citations
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
A second publication from the GEMSTONE-302 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
basicNature Cancer 2021177 citations
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalNature Cancer 2021501 citations
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
One of the most cited papers Europe PMC returns for Antoine Italiano at Institut Bergonié, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
translationalNature Cancer 2020185 citations
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma
It joins the pathology (adenosquamous), the transcriptome (basal-like) and the genome (KDM6A, MYC) into one account of the chemotherapy-resistant subtype, and shows a single biopsy can miss it.
collections
people
key papers
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinomaImmune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunityInterim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCMature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression